Addressing the challenges of diagnostics demand and supply: insights from an online global health discussion platform

Abstract

Several barriers challenge development, adoption and scale-up of diagnostics in low and middle income countries. An innovative global health discussion platform allows capturing insights from the global health community on factors driving demand and supply for diagnostics. We conducted a qualitative content analysis of the online discussion ‘Advancing Care Delivery: Driving Demand and Supply of Diagnostics’ organised by the Global Health Delivery Project (GHD) (http://www.ghdonline.org/) at Harvard University. The discussion, driven by 12 expert panellists, explored what must be done to develop delivery systems, business models, new technologies, interoperability standards, and governance mechanisms to ensure that patients receive the right diagnostic at the right time. The GHD Online (GHDonline) platform reaches over 19 000 members from 185 countries. Participants (N=99) in the diagnostics discussion included academics, non-governmental organisations, manufacturers, policymakers, and physicians. Data was coded and overarching categories analysed using qualitative data analysis software. Participants considered technical characteristics of diagnostics as smaller barriers to effective use of diagnostics compared with operational and health system challenges, such as logistics, poor fit with user needs, cost, workforce, infrastructure, access, weak regulation and political commitment. Suggested solutions included: health system strengthening with patient-centred delivery; strengthened innovation processes; improved knowledge base; harmonised guidelines and evaluation; supply chain innovations; and mechanisms for ensuring quality and capacity. Engaging and connecting different actors involved with diagnostic development and use is paramount for improving diagnostics. While the discussion participants were not representative of all actors involved, the platform enabled a discussion between globally acknowledged experts and physicians working in different countries.

How to implement new diagnostic products in low-resource settings: an end-to-end framework

“…Given that elements such as manufacturability, cost, distribution and product support greatly affect success, it is vital at this stage to consult delivery stakeholders (manufacturers if different from developer, procurers and distributors) to create realistic TPPs that are well aligned with the real implementation and scale-up needs 6. For example, challenges around affordability might require developers to explore technologies and formats with very low manufacturing costs in order to deliver the required product performance at significantly lower prices.…”

“…During the design process, the developer identifies an optimal product design that closely meets the desired performance specifications. End users and other stakeholders can provide valuable feedback on the prototype instrument in order to refine its design 6 24. In some cases, the relative importance of different features may need to be reassessed and used to make decisions on product design priorities.…”

“…Diagnostics developers from high-income countries (HICs) often struggle with identifying and assessing end-user needs, navigating policy and regulatory requirements, developing pricing strategies, ascertaining funding mechanisms and implementing and supporting products in healthcare systems with limited infrastructure 4 5. A structured approach to product development that creates more clarity around the types of activities required in low- and middle-income countries (LMICs) could help developers better navigate these challenges 6…”

Sensor-as-a-Service: Convergence of Sensor Analytic Point Solutions (SNAPS) and Pay-A-Penny-Per-Use (PAPPU) Paradigm as a Catalyst for Democratization of Healthcare in Underserved Communities

“…Recent advances in bacteria preconcentration and the diagnosis of TB and multi-drug resistant tuberculosis (MDR-TB) include sophisticated techniques such as Xpert MTB/RIF, TB beads, liquid culture, centrifugation, filtration, and line probe assays [43][44][45][46][47]. However, these techniques are not necessarily accessible or affordable for those who need them the most [48]. Considering the high accuracy (~97%) and specificity (~99%) of the Xpert system relative to the culture standard [36], the World Health Organization issued a recommendation in 2010 to use Xpert MTB/RIF for the diagnosis of all persons with signs and symptoms of TB.…”

Virus-Like Particles and Magnetic Microspheres Provide a Flexible and Sustainable Multiplexed Alphavirus Immunodiagnostic Platform

“…While these immunodiagnostic technologies are relatively unsophisticated, development of sensitive and specific antibodies and antigens required for an immunoassay is often a rate-limiting step. These immunodiagnostic reagents must be sensitive, specific, robust, and most importantly, sustainable (4).…”